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Severe acute respiratory syndrome coronavirus (SARS-CoV) is an important emerging virus that is highly
pathogenic in aged populations and is maintained with great diversity in zoonotic reservoirs. While a variety
of vaccine platforms have shown efficacy in young-animal models and against homologous viral strains, vaccine
efficacy has not been thoroughly evaluated using highly pathogenic variants that replicate the acute end stage
lung disease phenotypes seen during the human epidemic. Using an adjuvanted and an unadjuvanted double-
inactivated SARS-CoV (DIV) vaccine, we demonstrate an eosinophilic immunopathology in aged mice com-
parable to that seen in mice immunized with the SARS nucleocapsid protein, and poor protection against a
nonlethal heterologous challenge. In young and 1-year-old animals, we demonstrate that adjuvanted DIV
vaccine provides protection against lethal disease in young animals following homologous and heterologous
challenge, although enhanced immune pathology and eosinophilia are evident following heterologous chal-
lenge. In the absence of alum, DIV vaccine performed poorly in young animals challenged with lethal
homologous or heterologous strains. In contrast, DIV vaccines (both adjuvanted and unadjuvanted) performed
poorly in aged-animal models. Importantly, aged animals displayed increased eosinophilic immune pathology
in the lungs and were not protected against significant virus replication. These data raise significant concerns
regarding DIV vaccine safety and highlight the need for additional studies of the molecular mechanisms
governing DIV-induced eosinophilia and vaccine failure, especially in the more vulnerable aged-animal models
of human disease.
Emerging in 2002 in Guandong Province, China, severe
acute respiratory syndrome (SARS) presented as an atypical
pneumonia with an overall mortality rate of 10 to 12%, but
exceeding 50% in aged (60-year-old) populations (3, 12, 36).
The etiological agent was the novel SARS coronavirus (SARS-
CoV), a zoonotic virus that likely emerged from bats and
spread into civets and raccoon dogs either concurrent with or
prior to the human epidemic (8, 22, 62). While the epidemic
strain was controlled by aggressive public health intervention
strategies, the possibility of a reemergence is fueled by the
presence of SARS-like CoV strains circulating in animal res-
ervoirs (22, 23, 35). Indeed, phylogenetic analysis of outbreak
strains isolated during the late 2003/early 2004 epidemic sug-
gest multiple independent emergences into the human popu-
lation (49, 62).
SARS-CoV is a cytoplasmically replicating, positive-polarity,
single-stranded RNA (ssRNA) virus with three major mem-
brane-bound structural proteins, spike (S), envelope (E), and
membrane (M); several unique glycoproteins; and one struc-
tural protein within the virus core, the nucleocapsid (N) pro-
tein. Multiple candidate antiviral and immunomodulatory
therapeutics have been developed in response to the epidemic,
and vaccines would likely be a major tool in controlling any
new SARS-CoV outbreak (51). Key to the development of
effective SARS vaccines appears to be the generation of neu-
tralizing antibodies targeting the S glycoprotein, which provide
complete protection upon passive transfer and are consistently
associated with protection in multiple vaccine formulations
(15, 44, 52, 67). SARS vaccine strategies consist of varied
formulations of inactivated (24, 40), live attenuated (33), re-
combinant subunit (41), DNA (28, 60), or subunit-vectored
vaccines (2, 11, 13, 48). Live attenuated vaccines with deletions
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in nonessential proteins show some efficacy in young mice, but
low antibody titers preclude sterilizing immunity, and they
remain untested in more vulnerable aged animals (33). Vec-
tored vaccines incorporating the spike glycoprotein alone show
significant protection but are limited by strain specificity and
immunosenescence (48). Inactivated whole-virus vaccines have
the advantages of relative ease of production in large quanti-
ties, stable expression of conformation-dependent antigenic
epitopes, and the contribution of multiple viral immunogens.
However, the disadvantages of inactivated formulations in-
clude the risk of vaccine preparations containing infectious
virus, as well as the inclusion of antigenic determinants not
associated with protection that may unpredictably skew the
immune response (27). With few exceptions, SARS vaccine
formulations have not been tested against heterologous chal-
lenges in immunosenescent models of severe end stage lung
disease (48).
Effective SARS vaccines must meet several criteria, includ-
ing (i) the ability to protect against heterologous viral variants
that arise during independent emergence events, since many
S-targeted antibodies have significantly reduced neutralization
titers against heterologous spike glycoproteins (11, 19, 44); (ii)
the ability to elicit robust immune responses in elderly popu-
lations that are difficult to immunize and at increased risk for
SARS-CoV-induced morbidity and mortality (14, 29); and (iii)
avoidance of adverse vaccine outcomes, such as the vaccine-
induced immune pathology that has been demonstrated fol-
lowing vaccination with the SARS N protein (11, 61). Whole
inactivated SARS-CoV vaccines have demonstrated efficacy in
young-animal models, generating high titers of neutralizing
antibodies, yet most challenge studies have used a virus repli-
cation model devoid of clinical disease (17, 46, 50). In humans,
inactivated SARS-CoV vaccines have been shown to induce
neutralizing antibodies in healthy young subjects in phase 1
clinical trials (24, 28, 41). However, in neither humans nor
animal models have inactivated vaccines been assessed for
their ability to provide protection in aged populations or to
protect against heterologous challenges. Given the severity of
disease in aged populations and the possibility that emergent
SARS viruses will be antigenically distinct from the 2002 epi-
demic strain, animal models that capture severe age-related
disease and allow assessment of heterologous SARS challenges
are essential for the preclinical validation of any vaccine or
therapeutic candidate. The aged BALB/c mouse model repro-
duces age-related susceptibility to SARS-CoV disease similar
to that noted in human infections, including increased levels of
SARS-CoV replication, more severe clinical disease, and en-
hanced pulmonary histopathology (42, 45, 59). When chal-
lenged with zoonotic and human chimeric SARS-CoV incor-
porating variant spike glycoproteins, the aged BALB/c mouse
model reproduces severe lung damage associated with human
disease, including diffuse alveolar damage, hyaline membrane
formation, and death, thereby also providing a model for as-
sessing vaccine-mediated protection against heterologous vi-
ruses (45).
To test these hypotheses, we characterize the efficacy of an
inactivated whole SARS-CoV vaccine in a highly lethal homol-
ogous and heterologous challenge model that recapitulates the
age-related susceptibility and pathological findings seen in le-
thal human cases. The vaccine used was the CDC strain
(AY714217) of SARS-CoV, doubly inactivated by formalin
and UV irradiation, herein referred to as double-inactivated
virus (DIV) (50). The vaccine had initially been characterized
in tissue culture and young mice, where it was shown to induce
neutralizing antibodies and to provide protection from viral
replication. Adjuvanting with alum had minimal effect on the
serum neutralizing titers or protection in these young-mouse
protection studies (50). In this study, we chose to advance the
protection and safety studies of DIV by assessing homologous
and heterologous challenges in mice. We initially assess the
vaccine’s efficacy and potential for enhancement in a nonlethal
animal model using icGD03-S. This synthetically derived virus
incorporates the spike protein of a human strain isolated in
2004, providing a human virus challenge that is nonetheless
divergent from the vaccine strain (45). Extending this protec-
tion study to the more stringent test of a lethal challenge, we
utilize a mouse-adapted virus, icMA15, which is lethal in both
young and old BALB/c mice and is minimally different from
the vaccine strain (39). A chimeric virus incorporating the
spike protein of a civet strain (HC/SZ/61/03) into the Urbani
backbone provides a lethal heterologous and zoonotic chal-
lenge model (45). These three viral challenge regimens, varied
adjuvants, and an aged-mouse model help to accurately model
potential challenges of vaccinating a human population against
future emergences involving a SARS-CoV-like zoonotic virus.
Our results demonstrate vaccine-induced enhancement of
eosinophilia and inflammatory response following challenge,
as well as failure to protect against heterologous challenge in
an aged-animal model. This work highlights the challenge of
vaccine design for zoonotic viruses, the need for developing
broadly neutralizing therapeutics, and the particular difficulty
of immunizing aged populations and offers new routes for
understanding SARS-CoV pathogenesis.
MATERIALS AND METHODS
The generation and characterization of each of the recombinant infectious
clones (icUrbani, icGD03-S, and icHC/SZ/61/03-S) have been described previ-
ously (45, 63). Briefly, all recombinant icSARS-CoV strains were propagated on
Vero E6 cells in Eagle’s minimal essential medium (MEM) (Invitrogen, Carls-
bad, CA) supplemented with 10% fetal calf serum (HyClone, Logan, UT),
kanamycin (0.25 g/ml), and gentamicin (0.05 g/ml) at 37°C in a humidified
CO2 incubator. All work was performed in a biological safety cabinet in a
biosafety level 3 (BSL3) laboratory containing redundant exhaust fans. Personnel
were equipped with powered air-purifying respirators with high-efficiency par-
ticulate air and organic vapor filters (3M, St. Paul, MN), wore Tyvek suits
(DuPont, Research Triangle Park, NC), and were double gloved.
Viruses and cells. The icGD03-S (AY525636) (47), icMA15 (FJ882957), and
icHC/SZ/61/03-S (45) strains of SARS-CoV were propagated on Vero E6 cells in
Eagle’s MEM supplemented with 10% fetal calf serum, kanamycin (0.25 g/ml),
and gentamicin (0.05 g/ml) at 37°C in a humidified CO2 incubator. For virus
growth, cultures of Vero E6 cells were infected at an approximate multiplicity of
infection (MOI) of 1 for 1 h, and the monolayer was washed twice with 2 ml of
phosphate-buffered saline (PBS) and then overlaid with complete medium. At
30 h postinfection, the supernatant was clarified by centrifugation at 1,600 rpm
for 10 min, aliquoted, and frozen at 70°C. Virus stocks were titrated by plaque
assay.
Mouse vaccination and challenge. Due to the poor availability of aged mice,
two slightly divergent mouse strains were utilized during the course of this
research. BALB/c mice (Harlan Laboratoriess, Indianapolis, IN) were chal-
lenged with lethal viruses (icMA15 and icHC/SZ/61/03-S), while the National
Institute of Aging (NIA) provided BALB/cBy mice for nonlethal/epidemic strain
challenges. Prior studies in our laboratory have shown conserved susceptibility
phenotypes in these mouse strains following SARS-CoV challenge, with slightly
increased morbidity and mortality in the NIA (BALB/cBy) strain. Therefore, in
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the nonlethal icGD03-S challenge, we expected slightly more morbidity than
normally would have been predicted in Harlan mice.
Female BALB/cAnNHsd mice (young [6 to 8 weeks old] and aged [12 to 14
months old]; Harlan Laboratories, Indianapolis, IN) were separated into 4
groups of 12 young and 12 aged mice. The mice within each group were vacci-
nated by footpad injection with 20-l volumes consisting of 0.2 g of double-
inactivated SARS-CoV vaccine, 0.2 g of double-inactivated SARS-CoV vaccine
with alum, 0.2 g of inactivated influenza virus (iFlu), or 0.2 g of inactivated
influenza virus with alum. The mice were boosted with the same regimen 22 to
28 days later. Aged female BALB/cBy mice (12 to 14 months old; NIA) were
vaccinated with PBS-, alum-, or VAP (VEE [Venezuelan equine encephalitis
virus] replicon [VRP] adjuvanting particle)-adjuvanted iFlu (n  8, 10, and 9,
respectively) or DIV (n  10, 9, and 10, respectively) immunogen. The vaccine
formulations consisted of 0.2 g of DIV or iFlu plus either PBS, 0.69 mg/ml
alum, or 105 infectious units (IU) of VAP, a dose which had previously been
demonstrated to provide protective immunity in young mice (25, 54). These mice
were then boosted with the same regimen 22 to 28 days later.
We collected blood from tail veins prior to challenge with icMA15, icHC/SZ/
61/03, or icGD03-S on day 36 postvaccination. Mice were anesthetized with a
ketamine (1.3 mg/mouse)-xylazine (0.38 mg/mouse) mixture administered intra-
peritoneally in a 50-l volume. The mice were intranasally inoculated with 105
PFU of icMA15, icHC/SZ/61/03, or icGD03-S in 50-l volumes and weighed
daily. At 2 or 4 days postinfection, the mice were euthanized with isoflurane, and
lung and serum samples were collected for analysis. For studies involving VRP
vaccinations, 5-week-old female BALB/c mice were immunized with 105 IU of
VRPs expressing SARS-CoV N, a bat coronavirus (BtCoV.279) N, or hemag-
glutinin (HA) in a 10-l volume by footpad injections. Three weeks later, blood
was collected by the tail nick method for enzyme-linked immunosorbent assay
(ELISA), and the mice were boosted with 105 IU of the respective VRPs. Three
weeks postboost, blood was collected by tail nick for assessing antibody re-
sponses. The mice were moved to a satellite facility under BSL3 conditions,
acclimatized, and challenged with 105 PFU of recombinant MA15 (rMA15)
icGDO3 virus (48) by intranasal inoculation as described above.
All mice were housed under sterile conditions in individually ventilated Seal-
safe cages using the SlimLine system (Tecniplast, Exton, PA). Experimental
protocols were reviewed and approved by the Institutional Animal Care and Use
Committee at the University of North Carolina, Chapel Hill, NC.
Plaque assay titration of virus from lungs. One-quarter of each lung was taken
for determination of the viral titer. Samples were weighed and homogenized for
60 s at 6,000 rpm in four equivalent volumes of PBS to generate a 20% solution.
The solution was centrifuged at 13,000 rpm under aerosol containment in a table
top centrifuge for 5 min, the clarified supernatant was serially diluted in PBS, and
200-l volumes of the dilutions were placed onto monolayers of Vero E6 cells in
six-well plates. Following 1 h of incubation at 37°C, the cells were overlaid with
0.8% agarose-containing medium. Two days later, the plates were stained with
neutral red, and the plaques were counted.
Plaque reduction neutralization titer assays. We heat inactivated mouse se-
rum at 55°C for 30 min and then serially diluted it to 1:50, 1:100, 1:200, 1:400, and
1:800 in PBS to a volume of 125 l. Next, we added 125 l of PBS containing 125
PFU of icSARS-CoV to each serum dilution, incubated the virus-serum mixtures
at 37°C for 30 min, added 200 l of each mixture to confluent cultures of Vero
E6 monolayers, and allowed them to incubate at 37°C for 1 hour. Following the
1-h infection, we covered each monolayer with 4 ml of 0.8% agarose melted in
standard Vero E6 cell medium and resolved the plaques with neutral red staining
2 days later. Finally, we calculated the 50% plaque reduction neutralization titer
(PRNT50) values, the serum dilutions at which plaque formation was reduced by
50% relative to that of virus not treated with serum.
Lung histopathology. One-half of each lung was fixed in 4% paraformaldehyde
(PFA) in PBS (pH 7.4) for at least 7 days, embedded in paraffin, sectioned to 5
m, and stained with hemotoxylin and eosin (H&E). Sections were blindly
evaluated by W. Funkhouser for the extent of tissue damage and characterization
of inflammation.
Visual enumeration of eosinophils. Lung tissues were prepared as described
above and stained with H&E or Congo red (plus hematoxylin) (30). For each
slide, an initial assessment of gross lung pathology was followed by selection of
a lung section and enumeration of eosinophils within the viewing field at 400
magnification. Representative images were minimally and identically processed
to enhance contrast in Adobe Photoshop CS4. For both H&E- and Congo
red-stained slides, multiple 160-m2 sections proximate to airways were assessed,
and the eosinophils counted were averaged per lung.
Quantitative real-time reverse-transcription (RT)-PCR. One-quarter of a lung
from each mouse was placed into RNAlater (Ambion) for 4 days at 4°C and then
frozen at 70°C. Lung samples were transferred from RNAlater to TRIzol and
homogenized for 60 s at 6,000 rpm, and RNA was extracted by chloroform/
isopropanol precipitation. cDNA was prepared by standard protocols using ran-
dom hexamers and SuperScript II Reverse Transcriptase (Invitrogen). Quanti-
tative PCR was conducted on a Lightcycler 480II (Roche) using ABI TaqMan
Gene Expression Assays specific for mouse GAPDH (glyceraldehyde-3-phos-
phate dehydrogenase) or mouse interleukin 4 (IL-4), IL-5, gamma interferon
(IFN-), IL-13, CCL11 (eotaxin), or Cxcl1 Keratinocyte-derived chemokine
(KC). Relative quantification was calculated as the log10 fold change (2CT)
relative to mock-vaccinated, mock-challenged controls.
Flow cytometry. Mice vaccinated with PBS, DIV, or DIV plus alum were
challenged with 105 PFU of icHC/SZ/61/03, weighed and monitored daily for
morbidity, and euthanized 4 days postinfection by isoflurane inhalation. The
lungs were perfused with 10 ml PBS by cardiac puncture, dissected, manually
minced, and vigorously agitated for 2 h in digestion medium (RPMI, 10% fetal
bovine serum [FBS], 15 mM HEPES, 1.7 mg/ml DNase 1 [Sigma], 2.5 mg/ml
collagenase A [Roche], 1 streptomycin, 1 gentamicin). The lungs were then
passed through a 75-m cell strainer, resuspended in RPMI medium (RPMI,
10% FBS, 15 mM HEPES), and overlaid on a density gradient of iodixanol
diluted to a density of 1.079 gm/cm3 with RPMI 1640 containing 10% FBS
(Optiprep, Sigma-Aldrich Co., St. Louis, MO). Following centrifugation, cells
were collected from the interface and washed, and viable cells were counted with
a Countess automated cell counter (Invitrogen). The cells were then incubated
with the following panel of antibodies: allophycocyanin (APC) anti-leukocyte
common antigen (LCA), PE-Cy7 anti-CD11b, and phycoerythrin (PE)-Cy5 anti-
major histocompatibility complex (MHC) class II antigens, all from eBioscience
(San Diego, CA); fluorescein isothiocyanate (FITC) anti-Gr-1 and PE anti-
SiglecF, from BD-Pharmingen (San Diego, CA); and PE-Texas Red anti-CD11c
(Molecular Probes Invitrogen, Carlsbad, CA). Following staining, the cells were
washed with fluorescence-activated cell sorter (FACS) wash buffer (1 Hanks
balanced salt solution [HBSS], 1% FBS) and fixed with 2% formalin, and flow
cytometry was conducted on a CyAn ADP (Beckman-Coulter) with 300,000
live-cell events gathered per lung sample. Analysis was performed with Summit
software (version 5.2; Beckman-Coulter). First, we gated on LCA and CD11c
cells by plotting those parameters against forward scatter and gating on positive
cells. Then, Gr-1 was plotted against SigLecF (see Fig. 8A). SigLecF-high,
Gr-1-intermediate cells were selected, and CD11b signal versus CD11c signal
was plotted for cells in that region. CD11b, CD11c cells are classified as
eosinophils, while alveolar macrophages are CD11c (see Fig. 8b). After gating
on LCA and CD11c cells, Gr-1-positive cells are classified as neutrophils (see
Fig. 8a). Of the cells that remain after gating out SiglecF cells and neutrophils,
we classify MHC class II-negative, CD11b, and B220-negative cells as mono-
cyte-derived dendritic cells (mDCs). The cell counts per lung were calculated as
the product of the total viable lung cell population by the percentage of gated
cells in live-cell events. We used a two-factor analysis of variance (ANOVA) to
assess the statistical significance of age and vaccine on the overall number of
cells. If the ANOVA determined a factor was significant, post hoc analyses using
Tukey’s honestly significant differences (HSD) were used to further determine
the effects of treatment on cell counts.
Enzyme-linked immunosorbent assay. Antigen-specific IgG and IgG subiso-
type titers were determined by ELISA. Briefly, purified recombinant SARS N
protein or S protein was coupled to high-binding 96-well ELISA plates (Greiner)
in basic carbonate buffer (pH  9.6). After washing with ELISA wash buffer
(EWB) (PBS with 0.016% Tween 20), diluted serum was added to the wells in
EWB with 10% blocking buffer (Sigma-Aldrich). After 2 h at 4°C, the plates were
washed again, and horseradish peroxidase-conjugated goat anti-mouse IgG,
IgG1, or IgG2a was added to the appropriate wells diluted in EWB plus blocking
buffer. After another 2 h, chromogenic substrate (o-phenylenediamine in citrate
buffer with added hydrogen peroxide) was added to each well. After 30 min, the
reaction was stopped with the addition of 0.1 M sodium fluoride and read at 450
nm. A sigmoidal curve was fit to each set of optical density (OD) versus log10
serum dilution values using the curve-fitting software of the SigmaPlot graphics
package (Systat Software, Inc.), and the inflection point (where the OD is
one-half of the maximum value recorded for that isotype-antigen combination) is
calculated and reported as the “half-max titer.”
RESULTS
DIV provides partial protection against nonlethal heterolo-
gous challenge in aged animals. The efficacy of double-inacti-
vated SARS-CoV vaccines has not been evaluated in aged
animals, which show immunosenescence, increased suscepti-
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bility to clinical disease, and increased pathology, reflecting
conditions in the more vulnerable SARS-CoV-infected aged
populations (48, 50). One-year-old National Institute of Aging
mice were vaccinated with double-inactivated SARS vaccine
(DIV) or nonspecific immunogen (iFlu) in unadjuvanted form,
adjuvanted with alum, or adjuvanted with VAP. SARS-specific
total IgG responses, as measured by ELISA, show a significant
increase in the alum-adjuvanted group compared to the PBS-
adjuvanted group for both N-specific (3.580 versus 2.625 log10
half-max titer) and S-specific (3.743 versus 2.781 log10 half-max
titer) antibodies (Fig. 1A). Unexpectedly, the VAP adjuvant
nearly ablated total IgG antibody compared to PBS, reducing
total S- and N-specific antibodies to titers of 0.7432 and 1.182
log10 half-max, respectively (Fig. 1A). The alum-adjuvanted
DIV induced a strong skew in the N- and S-specific antibodies
toward IgG1, a subtype associated with Th2 immune re-
sponses, while the nonadjuvanted DIV resulted in a more
balanced or IgG2a-skewed antibody population (Fig. 1B).
To assess protection from heterologous SARS infection, the
aged DIV-vaccinated mice were challenged with 105 PFU of
icGD03-S, a recombinant heterologous human strain that
closely resembles zoonotic strains circulating in 2004. Both
DIV- and DIV-plus-alum-vaccinated groups showed signifi-
cant, though incomplete, reductions in morbidity (as measured
FIG. 1. DIV vaccination and nonlethal heterologous challenge in aged animals. (A) Log10 half-maximum ELISA titers for anti-N and anti-S
total IgG antibodies following DIV immunization. One-year-old aged NIA mice were immunized with DIV (n  10), DIV plus alum (n  9), or
DIV plus VAP (n  9). The values were statistically compared by a Mann-Whitney test. The error bars indicate standard deviations. (B) Log10
half-maximum ELISA titers of IgG1 versus IgG2a subtypes. Each point represents log10 IgG1 and IgG2a half-max titers for a single mouse.
(C) Representative images (400 magnification) of eosinophil infiltration in icGD03-S-challenged mice following DIV or iFlu vaccination
regimens. Lungs taken 4 days postinfection were sectioned and stained with Congo red, a reliable and specific stain for eosinophils (arrows).
(D) Box and whisker counts of eosinophils proximal to airways in icGD03-S-challenged aged mice, with the range shown by the whiskers.
Eosinophils were counted in 4 160-m2 regions proximal to airways (5 airways per mouse). The counts were statistically compared to those of
adjuvanted controls by a t test with Welch’s correction. (E) Mice challenged with the icGD03-S virus were weighed daily and visually assessed for
morbidity. DIV and DIV-plus-alum immunogens significantly reduced the morbidity associated with icGD03-S challenge by day 4 postchallenge.
(F) Mice were harvested on day 4, and one-quarter of the lung was homogenized, with the titer determined by plaque assay. Lung titers were
sporadically reduced for both the DIV and DIV-plus-alum groups, with only DIV plus alum reaching statistical significance by the Mann-Whitney
test. *, P 	 0.05; **, P 	0.01; †, P 	0.001; ‡, P 	0.0001.
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by weight loss) by day 4 postinfection, while none of the non-
specific-vaccination groups showed any reduction in morbidity
or lung viral titer by 4 days postinfection (Fig. 1E and F). The
VAP-adjuvanted DIV group predictably showed no reduction
in morbidity or titer, consistent with the failure of DIV plus
VAP to induce SARS-specific antibody responses in the aged
animals (data not shown). When the viral titers in the lungs
were assessed, only the DIV-plus-alum group showed signifi-
cant reductions in day 4 lung titers, while all other groups,
including non-adjuvanted DIV, showed high levels of viral
replication (Fig. 1F). These results demonstrate that while
DIV does provide some heterologous protection in highly sus-
ceptible aged populations, the vaccine is unable to provide
complete protection from either viral replication or virus-in-
duced morbidity.
Previous work by our group and others has demonstrated
that vaccination with SARS N protein fails to protect from
SARS replication while driving a vaccine-induced eosinophilic
pathology. Therefore, given that none of the DIV vaccine
strategies resulted in complete protection from viral replica-
tion in the aged animals, we assessed whether any of the
vaccine groups exhibited signs of eosinophilic immune pathol-
ogy. Importantly, both the DIV and DIV-plus-alum groups
showed increased numbers of eosinophils in the lungs follow-
ing challenge (Fig. 1C). Mice vaccinated with iFlu and iFlu-
plus-alum showed a low number of eosinophils in regions prox-
imate to airways by Congo red staining: both iFlu and iFlu-
plus-alum groups had a median count of 1.0 eosinophil per
region (Fig. 1D). Both DIV- and DIV-plus-alum-vaccinated
groups showed significant increases in eosinophil counts over
the comparable nonspecific immune groups at 5.0 and 35.0
eosinophils per region, respectively. Further, adjuvanting with
alum significantly increased the eosinophil influx compared to
DIV alone.
Immunization of young and aged animals. Few candidate
vaccines have been tested in aged animals following homolo-
gous and heterologous lethal challenge, and no whole-virus
vaccines have been so tested. Therefore, we assessed whether
the DIV formulations would protect against heterologous and
homologous lethal challenges in young- and aged-animal mod-
els. As a control, vaccination with inactivated influenza virus
with or without alum did not induce detectable levels of anti-
SARS (Urbani) antibody in either 12-week-old young or 59-
week-old aged mice (data not shown). When young mice were
vaccinated with 0.2 g of the SARS-CoV DIV, 8/16 generated
detectable levels of SARS neutralizing antibody titers. Vacci-
nation with DIV plus alum induced detectable levels of neu-
tralizing antibody in 15/15 mice and at significantly increased
PRNT levels compared to DIV alone (Fig. 2). Specifically, the
mean (
standard deviation [SD]) PRNT50 value for DIV
alone was 221 
 220, which significantly differed from the
DIV-plus-alum group’s neutralizing titer of 2,710 
 992 (Fig.
2). Importantly, DIV alone did not induce detectable levels of
anti-SARS antibodies in aged mice, while the addition of alum
increased the response in aged animals, with 8/14 aged animals
generating detectable levels of neutralizing antibodies. The
mean PRNT50 value was 425 
 806, significantly reduced by
about 6-fold compared with DIV-plus-alum-vaccinated young
animals. Thus, in young and aged animals, the presence of
alum in the DIV vaccine formula significantly improved the
induction of SARS-CoV neutralizing antibody: from moderate
to high levels in young animals and from unmeasurable to
moderate levels in aged animals.
Lethal mouse-adapted and zoonotic challenges in young
mice. To directly assess vaccine-mediated protection from le-
thal disease in young and old animals, mice were challenged
either with the homologous mouse-adapted icMA15 virus or
with the heterologous zoonotic virus icHC/SZ/61/03-S. In
young animals, DIV provided partial protection, increasing
survival following challenge with icMA15 from 0% to 83.3%
and significantly reducing morbidity by day 3 (P 	 0.01;
2-tailed Mann-Whitney test). In contrast, DIV plus alum pro-
vided complete protection from morbidity and mortality by 4
days postinfection in icMA15-challenged mice (Fig. 3A and B).
When young mice were challenged with icHC/SZ/61/03-S, both
the DIV alone and DIV-plus-alum groups were provided com-
plete protection from mortality. The DIV-plus-alum group
showed complete protection from morbidity, while DIV-im-
munized groups showed mild weight loss. The nonspecifically
vaccinated groups (iFlu and iFlu-plus-alum) lost 20% of
their starting weight by day 3 (icMA15) or day 4 (icHC/SZ/61/
03-S) postinfection, respectively. Furthermore, the iFlu- and
iFlu-plus-alum-vaccinated icMA15-infected animals showed
0% survival by day 4, while the same groups challenged with
icHC/SZ/61/03-S showed 67% and 50% survival, respectively.
In short, although DIV-mediated protection was not complete,
there was partial protection from homologous and heterolo-
gous lethal challenges in young animals, and this protection
from weight loss and death was enhanced by the inclusion of
alum adjuvant.
When viral titers were assessed in the lungs at day 4 postin-
fection, young mice vaccinated with DIV plus alum showed no
detectable viral titer following either viral challenge (Fig. 3C).
FIG. 2. Neutralizing antibody titers of vaccinated mice. Shown are
PRNT50 values of sera collected from young and aged mice vaccinated
with DIV or DIV plus alum. Neutralizing titers were significantly
reduced in both aged vaccination groups compared to the young
groups (DIV, P 	 0.01; DIV plus alum, P 	 0.0001; Fisher exact test).
Alum adjuvant significantly increased neutralization titers for both
young and aged animals (, P 	 0.01; ‡, P 	 0.0001; 2-tailed Mann-
Whitney test). No neutralizing antibody was detectable for young or
aged mice vaccinated with iFlu (n  15 and n  16, respectively) or
iFlu plus alum (n  14 and n  15, respectively) (data not shown).
PRNT50 values below the limit of detection were assigned a value of 50
and those above the upper limit of quantification (ULOQ) a value of
3,200. (lower limit of quantification [LLOQ]  100; ULOQ  1,600).
VOL. 85, 2011 INACTIVATED SARS-CoV VACCINE EFFICACY IN THE AGED 12205
In contrast, for DIV alone, lung titers following icMA15 chal-
lenge were reduced to undetectable levels in only 1 of 5 sur-
viving mice, and the remaining 4 had titers ranging from 5.65
to 6.41 log10 PFU/g. Following icHC/SZ/61/03-S challenge,
viral titers in DIV-vaccinated mice were reduced to undetect-
able levels for all but 1 mouse (3.74 log10 PFU/g). In compar-
ison, the iFlu-immunized groups had titers ranging from 3.65
to 4.83 log10 PFU/g (iFlu) and 4.72 to 5.14 log10 PFU/g (iFlu
plus alum). Therefore, in agreement with morbidity data, DIV
plus alum was able to provide complete protection in young
animals, while DIV alone reduced but did not eliminate viral
replication following homologous or heterologous challenge.
Lethal mouse-adapted and zoonotic challenges in aged
mice. In stark contrast to the encouraging results seen in young
animals, 1-year-old aged animals vaccinated with either DIV
alone or DIV-plus-alum did not show complete protection
from mortality, and both groups demonstrated significant mor-
bidity, with weight loss and high levels of viral replication. As
in young animals, iFlu-vaccinated groups showed an 20%
weight loss by day 3 (icMA15) or 4 (icHC/SZ/61/03-S) postin-
fection. Survival following icMA15 challenge was 16.7% and
0% on day 4 for iFlu and iFlu-plus-alum, respectively; follow-
ing icHC/SZ/61/03-S challenge, the rate was 16.7% for each
treatment. Unlike young animals, aged groups vaccinated with
DIV alone did not show promising reductions in morbidity,
mortality, or viral titer following these lethal challenges (Fig.
3). icMA15- or icHC/SZ/61/03-S-challenged groups vaccinated
with DIV alone had greater than 20% weight loss by day 4, and
the DIV immunization provided no significant increases in
survival for either virus challenge (16.7% for icMA15 and
66.7% for icHC/SZ/61/03-S). The one surviving mouse follow-
ing icMA15 challenge had a lung viral titer of 6.70 log10 PFU/g,
and following icHC/SZ/61/03-S challenge, the surviving mice
had lung titers ranging from 3.89 to 4.44 log10 PFU/g, which
was slightly reduced compared to the peak titers seen in sur-
viving iFlu-vaccinated control mice (4.83 and 4.98 log10 PFU/
FIG. 3. Morbidity and mortality of lethal mouse-adapted and zoonotic challenges following DIV immunization. (A and B) Young and aged
mice were vaccinated with iFlu, iFlu plus alum, DIV, or DIV plus alum (n  6 per group) and subsequently mock infected (data not shown) or
challenged with 105 PFU of icMA15 or icHC/SZ/61/03-S. The mice were weighed daily and monitored for morbidity (A) and mortality (B).
(C) Four days postinfection, lungs were harvested, and the viral load was assessed by plaque assay. Values were statistically compared by
Mann-Whitney test. The error bars indicate standard deviations.
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g). In contrast to DIV alone, DIV plus alum did significantly
increase survival rates for aged mice after both icMA15 and
icHC/SZ/61/03-S challenges compared to the iFlu-plus-alum-
immunized groups. Following icMA15 challenge, aged mice
vaccinated with DIV plus alum showed 83.3% survival by day
4 (versus 0% for iFlu plus alum; P	 0.01; 2-tailed Fisher exact
test), and the comparable group challenged with icHC/SZ/61/
03-S showed 100% survival (versus 16.7% for iFlu plus alum;
P	 0.01; 2-tailed Fisher exact test). However, mice in both the
icMA15- and icHC/SZ/61/03-S-challenged groups had signifi-
cant weight loss compared to mock-infected controls (P	 0.05
for both) (Fig. 3A). Additionally, DIV plus alum reduced lung
titers to undetectable levels by day 4 in only 3 of the 5 surviving
icMA15-challenged animals and did not eliminate virus from
any of the surviving icHC/SZ/61/03-S-challenged animals de-
spite 100% survival in those animals (Fig. 3C).
Pathological findings in icMA15- or icHC/SZ/61/03-S-chal-
lenged animals. DIV alone failed to provide complete protec-
tion from SARS replication and disease in both young and old
animals, while DIV plus alum failed to prevent weight loss in
aged animals, suggesting that neither vaccine formulation
would protect from SARS-induced respiratory pathology. We
therefore evaluated the lungs of animals from each of the
vaccination groups for vaccine-induced pathology. Lethal chal-
lenges to naïve mice result in a denuding bronchiolitis and
apoptotic debris in the airways of both young and old animals.
Young mice challenged with icHC/SZ/61/03-S displayed diffuse
parenchymal alveolitis, while challenge with icMA15, and both
challenges to aged mice, demonstrated additional pathology,
including diffuse alveolar damage (DAD) and hyaline mem-
brane formation, both hallmarks of acute respiratory distress
syndrome (ARDS) in SARS cases (young, Fig. 4; aged, Fig. 5).
Young animals vaccinated with DIV suffered significant
pathological changes that were generally worse in icMA15-
than icHC/SZ/61/03-S-challenged animals. Compared to
mock-vaccinated groups, the DIV-vaccinated groups showed
increased perivascular and peribronchial cuffing, as well as
scattered infiltrates in the parenchyma, including neutrophils,
alveolar macrophages, and eosinophils (Fig. 4). DIV-vacci-
nated aged animals showed greater pathology than young an-
FIG. 4. Pathology in young mice challenged with icMA15 or icHC/SZ/61/03-S. Shown are representative images of H&E-stained lung
panorama (100), airway (400), and parenchyma (400) sections from young mice vaccinated with the indicated immunogen and challenged
with icMA15 or icHC/SZ/61/03-S. TB, terminal bronchiole; AD, alveolar duct; black arrows, denuded airway; blue arrows, acute alveolitis and
septal congestion; green arrows, peribronchovascular cuffing; red arrows, hyaline membrane.
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imals, particularly perivascular cuffing and interstitial thicken-
ing (Fig. 5). These results indicate that not only did the DIV
vaccine fail to protect from viral replication and morbidity/
mortality, but the vaccine actually promoted the development
of enhanced inflammatory damage within the lungs.
The adjuvanted vaccine, DIV plus alum, well protected
young mice from icMA15 challenge, showing minimal patho-
logical changes. However, despite good protection from weight
loss or lethality, DIV-plus-alum icHC/SZ/61/03-S-challenged
mice showed histopathology more extensive than that in un-
vaccinated mice, with increased peribronchiovascular cuffing
consisting of mature lymphocytes, macrophages, and eosino-
phils (Fig. 4). In aged animals, DIV plus alum provided little
protection against either challenge, demonstrating pathology
beyond that in the unvaccinated mice, with additional perivas-
cular and peribronchial cuffing, as well as fibrinous exudates in
the alveolar parenchyma (Fig. 5C and D).
Aged animals have increased Th2 effector and eosinophil-
associated cytokine mRNA. Given the Th2-associated skew in
antibody profiles (Fig. 2) and the broad influx of inflammatory
cells in vaccinated mice (Fig. 4 and 5), we used quantitative
RT-PCR to analyze in vivo cytokine mRNA expression follow-
ing vaccination and challenge (Fig. 6). Aged mice vaccinated
with DIV plus alum and challenged with icHC/SZ/61/03 had
elevated mRNA levels of Th2 effector cytokines, including
IL-13 and IL-5, at 2 and 4 days postinfection (P 	 0.01 for
each). The eosinophil chemoattractant CCL11 (eotaxin) was
significantly increased in the lungs of vaccinated mice at both
2 and 4 days postinfection (P 	 0.01). In contrast, IL-4 and
IFN- showed no significant changes at these time points (the
earliest of which is day 2), and the neutrophil-associated
chemokine, Cxcl1, was elevated in mock-vaccinated rather
than DIV-vaccinated groups (P 	 0.05).
Vaccination and lethal challenge induce an eosinophilic pul-
monary influx. The presence of high numbers of eosinophils
among the inflammatory infiltrates following vaccination and
subsequent challenge has been a consistent observation asso-
ciated with respiratory syncytial virus (RSV)- and measles vac-
cine-induced immunopathology and was observed in vaccina-
tion experiments with the SARS-nucleocapsid immunogen,
peaking at 4 days postinfection (11, 61). To assess the eosino-
philic influx following whole-virus immunization and lethal
challenge, we blindly assessed H&E-stained lung sections of
aged mice challenged with HC/SZ/61/03-S and enumerated
eosinophils proximate to airways. Representative images
(400 magnification) of regions proximate to airways are
shown in Fig. 7A, with counts of eosinophils per 160 m2 in
Fig. 7B. A median 9.0 eosinophils per 160 m2 were present
around the airways of DIV-vaccinated groups, comparable to
the median 11.0 present in DIV-plus-alum groups. These
FIG. 5. Pathology following immunization and subsequent lethal challenge in aged Harlan mice. Shown are representative H&E-stained
sections of panorama (100), airway (400), vasculature (400), and parenchyma (400) lung regions from aged mice: (A) mock infected;
(B) iFlu plus alum vaccinated, icHC/SZ/61/03-S challenge; (C) DIV plus alum vaccinated, icHC/SZ/61/03-S challenge; (D) DIV plus alum
vaccinated, icMA15 challenge. See the legend to Fig. 4 for arrow definitions.
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counts are significantly higher than in the iFlu (median, 1.0)
and iFlu-plus-alum (median, 0.0) groups, respectively (Fig.
7B). These data suggested that increased eosinophilia occurs
following DIV and DIV-plus-alum vaccination in young and
aged animals, especially following heterologous challenge.
To precisely characterize the inflammatory infiltrate follow-
ing DIV vaccination, we challenged PBS-, DIV-, or DIV-plus-
alum-immunized young and aged mice with icHC/SZ/61/03-S
and examined whole lungs by flow cytometric analysis at 4 days
postinfection. Eosinophils, defined as LCA SiglecF
CD11b CD11c populations (Fig. 8), were significantly in-
creased in all vaccinated compared to unvaccinated popula-
tions following lethal challenge (Fig. 8A [F2,32  14.739; P 	
1  104] and 9A). Post hoc analysis using Tukey’s HSD
showed that both DIV (P  0.0003433) and DIV-plus-alum
(P 	 1  104) groups had significantly increased numbers of
eosinophils compared to PBS-immunized animals. Adjuvant
had no measurable effect on the eosinophilic influx, as DIV-
and DIV-plus-alum-immunized mice did not have statistically
significant differences in their overall numbers of eosinophils
in either age group. Importantly, the elevated eosinophil
counts were comparable between young and aged populations
despite divergent clinical presentations. Further analysis of the
inflammatory cell infiltrates of vaccinated mice showed a
strong influence of age on the neutrophil (F1,32  22.0339; P	
1  104) and monocytic dendritic cell (F1,32  26.681; P 	
1  104) influx, with both cell populations significantly in-
creased in aged relative to young animals (Fig. 9B and D).
Alveolar macrophage counts showed no significant differences
compared to mock-vaccinated mice in either young or aged
animals (Fig. 9C). Finally, the vaccinated animals showed sig-
nificantly lower monocytic DC counts by day 4 postchallenge,
independent of age (F2,32  11.18; P  0.0002079), and post
FIG. 6. Cytokine and chemokine mRNA expression profiles in
aged mice. RNA was taken from the lungs of aged mice vaccinated
with DIV plus alum and challenged with icHC/SZ/61/03 at 2 and 4 days
postinfection. Cytokine and chemokine mRNAs were measured by
quantitative real-time RT-PCR. The values are shown as log10 fold
change over an unvaccinated, unchallenged control. , P 	 0.05; ,
P 	 0.01. The error bars indicate standard deviations.
FIG. 7. Visual identification of eosinophils following lethal chal-
lenge. Eosinophils proximal to airways were counted in H&E-stained
sections of lung from aged icHC/SZ/61/03-S-infected mice. (A) Rep-
resentative images of regions counted, with eosinophils highlighted by
arrows. (B) Box and whisker counts of eosinophils proximal to airways
in icGD03-S-challenged aged mice, with ranges shown by the whiskers.
Eosinophils were counted in 4 160-m2 regions proximal to airways;
n  31 fields per group. Both DIV- and DIV-plus-alum-immunized
mice had visibly more eosinophils present following challenge than the
nonspecific-immunogen groups. ‡, P 	 0.0001; t test with Welch’s
correction.
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hoc analysis showed the differences were enhanced by the alum
adjuvant (P  0.04402) (Fig. 9D). Vaccination with DIV
clearly induces a strong eosinophilic infiltrate, independent of
age and regardless of whether it protects from morbidity, and
raises the possibility that DIV elicits immune pathology in the
face of heterologous SARS challenge.
Vaccine-induced eosinophilia is a common feature of N pro-
teins across group 2b coronaviruses. The data from our studies
collectively demonstrated that eosinophilic infiltration occurs
during DIV vaccination in both young and aged mouse popu-
lations, irrespective of the adjuvant and the challenge virus
used. Previous data from our laboratory have shown that vac-
cination with VRPs expressing SARS N protein (VRP N)
induces a similar eosinophilic phenotype while completely fail-
ing to protect against SARS CoV replication (11), suggesting
that the eosinophilia may be driven by SARS N protein. To
determine whether sequences intrinsic to SARS N protein or
an N protein from a group 2b coronavirus closely related to
SARS contribute to the induction of eosinophilia, we immu-
nized mice with VRPs expressing SARS N, the N gene from
BtCoV.279 (VRP 279 N), or an irrelevant antigen, VRP HA
(containing the hemagglutinin gene from the PR8 strain of
influenza virus). The BtCoV.279 N gene shares 95% sequence
homology with the SARS N gene, with conservation across all
the major domains of the N protein. Groups of mice immu-
nized with 105 IU of VRP N and VRP 279 N showed high
antibody titers post boost (data not shown) and were chal-
lenged with 105 PFU of rMA15 GDO3-S. This virus causes
15% weight loss in infected young BALB/c mice by day 4
postinfection (48). Mice from all the groups showed 15%
weight loss by day 4 postinfection, with virus titers ranging up
to 105 PFU (data not shown), indicating failure of N gene-
based vaccines to protect from virus replication. Histological
analysis of Congo red-stained lung sections showed increased
numbers of eosinophils proximal to airways in VRP N-immu-
nized mice compared to VRP HA-immunized mice (Fig. 10A).
Interestingly, enhanced influx of eosinophils was also found in
regions proximal to the airways in lungs from mice immunized
with VRP 279 N (Fig. 10A). Blind scoring of lung sections
indicated a median count of 25 eosinophils per region in VRP
N- and 279 N-immunized groups, whereas the VRP HA group
showed a median count of 3 per region (Fig. 10B). These data
clearly indicated that eosinophilia is driven by immune re-
sponses to sequences intrinsic to the SARS nucleocapsid pro-
tein and is conserved in N proteins across group 2b coronavi-
ruses.
DISCUSSION
The human coronaviruses HCoV 229E, HCoV OC43, and
SARS-CoV, each likely originating from animal reservoirs,
have demonstrated a high proclivity for coronaviruses to cross
the species barrier, adapt, and colonize the human host.
Though not currently circulating in humans, SARS-CoV, like
other zoonotic viruses, remains a significant reemerging dis-
ease threat given its maintenance in animal reservoirs. The
development of vaccines or therapeutics for SARS-CoV is
complicated by several challenges: the presence of a large
heterogeneous zoonotic reservoir of related strains, the resis-
tance of highly susceptible aged populations to vaccination,
and potential disease-enhancing complications of the vaccine
formulations (11, 48, 61). Though many experimental SARS
vaccine formulations have been developed, whole inactivated
virus vaccines have the advantage of large-scale production,
presentation of multiple epitopes, and conformation stability
(2, 11, 13, 28, 33, 48, 60).
Aged populations are classically difficult to vaccinate and
suffer increased disease pathologies following infection with a
FIG. 8. Flow cytometry gating strategy for cell populations. (A) Representative (PBS-vaccinated) plot of LCA lung cell populations.
Neutrophils were defined as live cells, LCA, Siglec, and GR-1 (green gate). SiglecF populations (black gate) from young and old mice were
further analyzed, as shown in panel B. (B) Representative images of eosinophil (CD11b and CD11c; blue gate) and alveolar macrophage
(CD11c; gray gate) gates for young and aged mice vaccinated with PBS, DIV, or DIV plus alum.
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variety of respiratory viruses, including influenza virus, RSV,
HCoV OC43, and SARS-CoV (14). Until recently, most pub-
lished assessments of SARS-CoV vaccine efficacy utilized mod-
els capable of assessing only viral replication or antibody in-
duction, and they are routinely conducted in animal models
that neglect important human disease presentations (11, 17, 33,
40, 46, 50). While necessary, these assessments are incomplete,
especially because more robust lethal-challenge models have
been developed that recapitulate severe end stage lung disease
pathologies and allow assessment of the potential complica-
tions of senescence (42, 43, 45, 48, 59). As shown here, a
vaccine that appears protective in young animals is much less
protective, and potentially pathogenic, in an aged-animal
model.
SARS-CoV emerged from a heterologous pool of closely
related animal strains, suggesting that future outbreak emer-
gences will likely involve strains with unique changes in the S
glycoprotein. The viral strains used in this study represent a
homologous lethal challenge virus (icMA15), as well as a non-
lethal human heterologous virus (icGD03-S) and a lethal zoo-
notic virus (icHC/SZ/61/03-S), which allowed us to directly test
whether DIV was capable of providing effective protection
against heterologous viruses in both young and highly suscep-
tible aged populations. Importantly, the DIV vaccine provided
partial protection against both homologous and heterologous
challenge in young animals, and this protective effect was en-
hanced by alum adjuvant. In contrast, even the adjuvanted
DIV vaccine failed to protect against virus-induced disease and
viral replication following homologous or heterologous chal-
lenge in aged animals. Perhaps most importantly, though DIV
plus alum protected against viral replication, disease, and re-
spiratory pathology following homologous viral challenge
(icMA15) in young animals, which is consistent with prior
reports (17, 46, 50), both DIV alone and DIV plus alum failed
to protect against respiratory pathology following homologous
challenge in aged animals, and both vaccine formulations
failed to protect against respiratory pathology following heter-
ologous challenge in mice of any age (Fig. 4 and 5). These
results further demonstrate the difficulty in eliciting protective
immune responses in highly susceptible elderly population and
indicate that in the face of a reemergent SARS virus, likely
antigenically heterologous from the 2002 outbreak strain, ex-
isting vaccine formulations are unlikely to provide protective
immunity.
In addition to the general failure of the DIV or DIV-plus-
alum vaccines to elicit protective immunity against heterolo-
gous SARS viruses or to provide protection even against ho-
mologous viral challenge in aged animals, both the DIV and
DIV-plus-alum vaccine formulations result in significantly en-
hanced immune pathology within the lungs compared to
control animals. Although adjuvanted DIV protected young
animals from morbidity and mortality following lethal chal-
lenges, the heterologous virus, icHC/SZ/61/03-S, induced a
lung pathology that was more severe in vaccinated than in
FIG. 9. Flow cytometric analysis of additional lung immune cell populations in young and aged mice following immunization and subsequent
lethal challenge. Mice challenged with icHC/SZ/61/03-S were sacrificed 4 days postinfection, and the lungs were stained with an eight-color panel.
Each point represents the cell population for an individual mouse. (A) Eosinophil counts for each of the vaccination groups (n  6 per group).
Regardless of the age of the mice, the eosinophil counts were significantly increased in both DIV- and DIV-plus-alum-immunized groups compared
to mock-vaccinated groups (F2,30  15.81; P 	 1  10
4). (B) For neutrophil counts, only age was a significant factor (F1,30  24.7150; P 
2.525e5). (C) Alveolar macrophage counts were significantly affected by immunogens in young, but not aged, animals, with post hoc analysis
indicating that both DIV and DIV-plus-alum groups significantly differed from mock-vaccinated groups (F2,30  3.5534; P  0.04121). (D) mDCs
were also significantly affected by age (F1,30  20.3622; P  9.193e05), as well as immunogen (F2,30  9.5681; P  0.0006107), with post hoc
analysis indicating significant reductions in mDC counts in DIV-plus-alum groups relative to both DIV and mock-vaccinated groups.
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unvaccinated mice (Fig. 4). This increased pathology was
not correlated with weight loss or mortality through day 4
postinfection (Fig. 3), but the increased immune infiltrate
indicates the vaccine is not fully protective against heterol-
ogous challenges. Further, in aged animals recalcitrant to
immunization, insufficient protective immunity correlated
with significantly increased immunopathology. Thus, evi-
dence of enhanced disease subsequent to vaccination was
evident in both heterologous challenge models and models
of immune senescence.
In each of the experiments conducted here, immunization
with the whole inactivated SARS vaccine induced increased
inflammatory infiltrates and pulmonary eosinophilia upon sub-
sequent challenge, demonstrating the potential for dangerous
clinical complications. This is consistent with two prior studies
of vaccine formulations incorporating SARS N, where N-spe-
cific immune responses resulted in enhanced eosinophilic im-
mune pathology (11, 61). This pathological signature is remi-
niscent of the two known human examples of vaccine-induced
immunopathology, atypical measles and enhanced RSV. For
both of these vaccine-induced immunopathologies, infection
subsequent to vaccination resulted in failure to control viral
replication, enhanced clinical disease, and a pathology charac-
terized by increased complement deposition and inflammation,
skewing toward Th2 responses, and eosinophilic influx (38).
The cytokine profiles of DIV-plus-alum-vaccinated and icHC/
SZ/61/03-challenged mice showed increased levels of Th2 ef-
fector cytokines and eosinophil chemokines (IL-5, IL-13, and
CCL11/eotaxin) compared to mock-vaccinated groups (Fig. 8).
In contrast, IFN- and IL-4 (Th1- and Th2-inducing cytokines)
were unchanged at 2 and 4 days postinfection, likely because
the peak mRNA levels for these inducing cytokines were ear-
lier in the time course of infection.
As previous studies had indicated peak eosinophilia at 4 days
postinfection, we assessed lung eosinophilia by both histopa-
thology and flow cytometry at this time point, quantifying sig-
nificant increases in the lungs of vaccinated mice following
CoV challenge (11). Eosinophilia was present independent of
age and independent of the alum adjuvant, although adjuvant
did increase the magnitude of the eosinophilic influx. DIV-
induced eosinophilic influx was present even in the animals
that were protected from morbidity and mortality. When this
protection was absent, eosinophilic immunopathology was a
dominant response more severe than the viral pathology seen
in unvaccinated controls. The eosinophilia in clinically pro-
tected animals may thus serve as a marker for potentially
pathogenic immune responses. While recent studies have ar-
gued that eosinophils are not the primary mediators of RSV
vaccine-induced immune pathology, they may contribute to in-
creased airway hyperresponsive conditions, including asthma, and
the pathophysiology of viral infections (6, 20).
Only eosinophils were consistently and significantly in-
creased in response to vaccination with DIV. In contrast, neu-
trophils and monocytic DC populations were significantly af-
fected by age, and monocytic DCs were decreased as a function
of vaccination. The greater population of neutrophils in aged
animals following challenge, independent of vaccination, sug-
gests that neutrophils may contribute to the increased severity
of SARS-CoV pathogenesis in the aged. A pathogenic role for
neutrophils in infection has been demonstrated for other res-
piratory viruses, including influenza virus, suggesting con-
served mechanisms of enhanced respiratory pathology in the
aged (26, 32).
SARS-CoV-targeted neutralizing antibodies are sufficient to
provide complete immunity against lethal SARS challenges in
multiple animal models and show evidence of controlling dis-
ease severity in human infections (4, 5, 11, 15, 44, 64, 67).
Spike-specific antibodies are both neutralizing and protective
up to 1 year postvaccination in mice, while anti-nucleocapsid
antibodies are neither neutralizing nor protective and, further,
appear to be detrimental to the longevity of protective anti-
bodies (11, 61). This deleterious effect does not appear to be an
antibody-dependent enhancement (ADE), since passive trans-
fer was unable to replicate the immunopathology, though low
posttransfer antibody titers preclude definitive exclusion of this
potential mechanism (11, 58).
While multiple major and minor SARS-CoV antigens are
incorporated in DIV, the N protein is the most likely agent of
FIG. 10. Eosinophilia influx is conserved across group 2b N pro-
teins. Young mice immunized with VRPs expressing the SARS N
protein (VRP N); the N protein from another group 2b bat coronavi-
rus, BtCoV.279 (VRP 279 N); or an irrelevant antigen (VRP-HA)
were challenged with icGD03, and the lungs were taken 4 days postin-
fection. (A) Representative images of lung sections (400) stained
with Congo red. The inset shows areas of dense inflammatory infiltrate
at higher magnification. (B) Both the SARS N and BtCoV.279 N
proteins induce a significant eosinophilic inflammatory influx com-
pared to the irrelevant antigen. ‡, P 	 0.0001.
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eosinophilic immunopathology (34). N is a strongly immuno-
genic protein (7, 9, 37, 65), is the most abundant protein in
infection (34), and has been shown in prior studies to induce
immunopathology when delivered in isolation (66). This nu-
cleocapsid-induced enhancement is not apparent in animals
with appreciable levels of neutralizing antibodies, indicating
that the induction of sufficiently neutralizing antibody re-
sponses can protect against SARS vaccine-induced immune
pathology. However, the results presented here clearly dem-
onstrate that in situations where individuals fail to mount pro-
tective anti-SARS responses, as is the case with heterologous
viral challenge or in immune senescence, the DIV-vaccinated
individuals are at significant risk for vaccine-induced immune
pathology. With this in mind, it will also be important to de-
termine the mechanisms by which N vaccination promotes
immune pathology, with a key question being whether pathol-
ogy is simply due to a nonprotective response against N or if N
vaccination actively skews the host immune response to pro-
mote immune pathology. Given that N has been shown to
modulate innate immunity and to act as an interferon antag-
onist, it is possible that N sufficiently alters the host immune
response to induce a Th2 skew and subsequent inflammatory
pathology (21). Indeed, immunization with N appears to in-
duce a Th2 skewing of the immune response regardless of the
adjuvant or formulation, suggesting the nucleocapsid protein
alone may well be the defining factor in CoV vaccine-induced
enhancement (11, 61; K. Long, D. Deming, R. Baric, and M.
Heise, unpublished data). Therefore, additional studies are
required to assess whether Ns innate immunomodulatory ac-
tivity is linked to the N vaccine-induced immune pathology,
and if so, whether this reflects a more general trait of viral
interferon antagonists in modulating the downstream host
adaptive immune response.
The major conclusion that can be drawn from these studies
is that although DIV SARS vaccines do elicit protection under
optimal conditions (homologous challenge in immunocompe-
tent individuals), more stringent challenges reveal likely fail-
ures. If DIV vaccine approaches are to be used for SARS in
the future, efforts must be made to improve the quality and
magnitude of the vaccine-induced immune response while lim-
iting the vaccine’s capacity to induce immune pathology. The
whole-virus vaccine used in this study was doubly inactivated
by UV irradiation and formalin (50). Formalin-inactivated vac-
cines are suggested to skew the immune response toward a Th2
response, producing higher levels of IL-4 and increasing the
relative contribution of IgG2a isotypes (31, 57). Previously,
formalin inactivation leading to a disruption of fusion glyco-
proteins or addition of carbonyl groups had been blamed for
the skewing of formalin-inactivated RSV (FI-RSV) immune
responses (31, 38). However, recent studies suggest that inac-
tivation by alternate methods still results in a Th2 skew and
immunopathology and that it is a failure of affinity maturation
that results in nonprotective responses and subsequent anti-
body-mediated enhancement (10, 57). Furthermore, the fact
that the DIV vaccine did elicit neutralizing antibody responses
and protection against homologous challenge in young animals
suggests that the DIV-induced pathology did not simply rep-
resent a loss of antigenic epitopes. Therefore, we do not think
the method of inactivation is necessarily responsible for immu-
nopathology associated with DIV, but rather, that any SARS
vaccines that include the nucleocapsid protein should be in-
vestigated for challenge-induced enhancement.
The results presented here reinforce the need to find meth-
ods to enhance the protective S-specific immune response
while minimizing potentially pathological anti-N response. Our
observation that immunization with BtCoV.279 N, which has
high sequence similarity to SARS N, also induces eosinophila
indicates that sequences intrinsic to N protein that are con-
served across group 2b coronaviruses may drive this immune-
mediated pathology. The amino acids responsible for this re-
sponse need to be mapped. Assessment of N-induced immune
pathology by sequentially divergent CoV N proteins may allow
the design of chimeric SARS CoVs that could serve as vaccines
devoid of immune pathology. In both young and aged mice,
adjuvanting with alum increases the immunogenicity of the
DIV, concordant with many earlier studies using this adjuvant
(50). In young mice, approximately one-half of the animals
mounted neutralizing antibodies following DIV vaccination,
and all achieved neutralizing titers when DIV was adjuvanted
with alum (Fig. 2). However, only half the aged mice were
capable of mounting neutralizing antibody titers to DIV plus
alum, and none mounted such responses without the adjuvant.
Alum is one of the few adjuvants approved for use in human
vaccine formulations and functions to stimulate Th2 immunity,
a potentially confounding factor in the induction of immuno-
pathology. We briefly assessed an alternative adjuvant, VAP,
which is reported to stimulate Th1 immunity (18, 53, 56, 57). In
contrast to reports of success in young mice, the VAP-adju-
vanted formulation in aged mice ablated rather than enhanced
the protective response to DIV; subsequently challenged mice
showed morbidity and mortality rates comparable to those in
unvaccinated controls (data not shown) (55, 56). While the
mechanism of this ablation has not been defined, the VAP
adjuvant likely functions through cross-presentation of exoge-
nous antigens within antigen-presenting cells, a process im-
paired in age-associated immunosenescence (16). VEE formu-
lations incorporating the wild-type 3000 glycoprotein show
better immunogenicity in aged animals, likely due to improved
cross-presentation over the attenuated 3014 glycoprotein, sug-
gesting that alternative VAP formulations may be more effec-
tive (48). Therefore, if DIV approaches are to be considered
for SARS or other respiratory coronaviruses, we feel that it will
be important to rigorously test the vaccine and potential adju-
vant in the aged-mouse model to assess both efficacy and po-
tential immune pathology in the face of immune senescence
and/or heterologous viral challenges.
Emergent zoonotic viruses present novel and shifting targets
for vaccine design. The clear deficiency of the double-inacti-
vated SARS vaccine against challenge models with divergent
spike glycoproteins highlights the need for vaccines that induce
broadly neutralizing immune responses. Further, impartial
conservation of viral antigens cannot be considered a benefit to
vaccine formulations for coronaviruses when select immuno-
gens induce detrimental immune responses upon challenge.
The N-induced pathogenic responses appear to be masked by
S-targeted neutralizing antibodies but become dominant once
the protective immunity wanes. In the case of SARS-like CoV,
we cannot expect zoonotic variation to reduce specificity for N
more readily than for S, as the S glycoproteins of multiple
isolates show greater sequence variation and readily evolve
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over the course of an epidemic (19, 22, 44). Further, the con-
servation of N across group 2b coronaviruses and the demon-
strated conservation of N-induced immunopathology raise the
possibility that challenge with nonepidemic coronavirus strains
may induce eosinophilic immunopathology in vaccinated pop-
ulations. Despite the difficulty of vaccine design for zoonotic
viruses such as coronaviruses, paramyxoviruses, and filoviruses,
a growing pool of sequence data for zoonotic isolates; the
rapidity of sequencing and isolation in the case of outbreaks;
synthetic-gene design; and the multiple vectored, inactivation,
or antibody-generating platform technologies available ensure
that vaccines can be readily formulated in case of novel out-
breaks (1). The challenge for researchers and clinicians is to
validate these vaccines in strong animal models and to confirm
and enhance vaccine efficacy in aged individuals. Identifying
the vaccine components that induce protective immunity in
aging individuals will be essential to protecting this vulnerable
population. The data presented here indicate that SARS-CoV,
coupled with a panel of heterologous zoonotic precursor vi-
ruses, represents a tractable model system to evaluate the
molecular mechanisms governing immunosenescence and its
impact on emerging virus pathogenesis and vaccine efficacy.
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